Accordingly, the next stage of treatment in patients with Hashimoto’s should include screening for thyroglobulin antibodies (anti-TG), anti-deamidated gliadin peptid (anti-DPG), endomysial antibodies (EMA), and anti-gliadin antibodies (AGA) to exclude subclinical celiac disease and NCGS. The gene discussed is TG; the disease is celiac disease.